HEALTH

Amid counterfeit product warning, Biotab recalls two lots of Extenze

BY Michael Johnsen

MONROVIA, Calif. — Biotab Nutraceuticals on Tuesday initiated a voluntary recall of two lots of Extenze nutritional supplement tablets.

Some packages bearing lot numbers 0709241 and 0509075 are counterfeit products containing undeclared drug ingredients that can pose a serious risk to health, the company stated.

Biotab learned about the problem after being notified by the Food and Drug Administration that lot 0709241 contains tadalafil and sildenafil, and lot 0509075 contains tadalafil and sibutramine. The counterfeit products are sold at retail nationwide in the form of carded four-packs (lot 0709241) and in the form of a box of thirty tablets divided into two 15-tablet blister packs (lot 0509075).

Tadalafil and sildenafil are drugs used to treat erectile dysfunction. These drugs may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.

Sibutramine is a controlled substance that was withdrawn from the market in October 2010 for safety reasons. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.

The counterfeit Extenze product is not manufactured, distributed or packaged by Biotab, but is falsely marked with the same lot numbers used by Biotab for its genuine product. Because it is very difficult to distinguish the counterfeit from the genuine product, Biotab decided to conduct this voluntary recall of the two affected lots. It is possible that there may be other counterfeit products on the market that have yet to be identified, the company cautioned.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Advanced BloodStop now available at CVS/pharmacy

BY Michael Johnsen

MOUNTAIN VIEW, Calif. — LifeScience Plus recently introduced Advanced BloodStop, a bandage that helps stop bleeding in less than one minute, at CVS/pharmacy.

“We are very excited to be able to offer this product through CVS,” stated Wayne Korteweg, COO of LifeScience Plus. “BloodStop is so much more effective and versatile than ordinary bandages; it’s an essential for any medicine cabinet, first aid kit or car for home or travel emergencies.”

The bandage looks and feels like ordinary cotton gauze when dry but transforms into a gel once it comes in contact with blood. BloodStop adheres to the skin’s surface and creates pressure to seal and protect the wound while stopping the bleeding. BloodStop is easily removed with water or saline.

Advanced BloodStop will retail for a suggested $10.99 to $13.99 for a package of five, individually-packaged, sterile gauzes.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

SleepRight adds nasal breathe aids to lineup

BY Michael Johnsen

KANSAS CITY, Mo. — Splintek Health Products recently launched its SleepRight nasal breathe aid — a snore-relieving product entry into the nasal strip category that retails for a suggested price of $11.99.

According to the company, the product reduces snoring, relieves nasal congestion and is adhesive-free and reusable. Flexible flares expand the nasal passages to significantly increase airflow, while forming to the shape of the user’s nose for a custom, comfortable fit. Each breathe aid is reusable and lasts up to 15 days.

The SleepRight brand heritage is within the dental guard segment with a no-boil product that helps prevent overnight teeth grinding.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?